Breast Cancer Patients clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

Adding immunotherapy to chemo for stage II-III breast cancer

This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).

Elacestrant and everolimus for ESR1-mutant advanced breast cancer

This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.

Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)

Imlunestrant and abemaciclib for early ER+ breast cancer

This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).

Hormone therapy with or without chemo for early breast cancer

This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.

Testing T-DXd or chemo for HER2-low or HR-positive breast cancer

This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.

Decision Support Tool for Advanced Breast Cancer

This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.

Neratinib before surgery for HER2-mutated invasive lobular breast cancer

This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.

Low-dose Capecitabine for High-risk Early Breast Cancer

This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.

Testing a new drug for advanced solid tumors

This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.

BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer

This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.

cmf chemotherapy for breast cancer in older adults

This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.

HLD-0117 study for metastatic breast cancer

This early-stage study tests a new drug called HLD-0117 in women whose metastatic breast cancer (cancer that has spread beyond the breast) has stopped responding to previous hormone and targeted therapies. The goal is to see if this drug can slow or shrink the cancer in patients who have limited options left.

Avoiding armpit lymph node removal in breast cancer

This trial tests whether it is safe to skip removing lymph nodes from the armpit when cancer has spread there but has been found by ultrasound. If you have breast cancer that has spread to armpit lymph nodes and are not getting chemotherapy before surgery, this study may be an option.

Testing a New Breast Cancer Drug for Women Who Can't Tolerate Current Therapy

This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.

3D-printed breast form study for women after mastectomy

This study tests a custom 3D-printed external breast form for people who had a mastectomy without reconstruction. It aims to see if it improves comfort and satisfaction.

Radiation and immunotherapy before surgery for HR+/HER2- breast cancer

This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.

Enhanced breast cancer screening for high-risk women

This study tests a more thorough breast cancer screening program using MRI and other imaging for women at high risk. It aims to detect cancer earlier, which may improve treatment options and outcomes.

Sparing memory during brain radiation for leptomeningeal metastases

This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.

Support program for breast cancer survivors

This study tests a navigation program to help breast cancer survivors get the support services they need after treatment. It is designed for people treated at the Stefanie Spielman Breast Center who may face extra barriers, such as being older, Black, Hispanic, or living in a rural area.

Plasma treatment during breast cancer lumpectomy

This trial tests a plasma treatment applied directly to the tumor site during a lumpectomy. It may help improve healing and reduce recurrence for people with early-stage breast cancer.

Megestrol Acetate for Fatigue in HER2+ Breast Cancer

This study tests whether a medication called megestrol acetate can help reduce severe tiredness and fatigue in people with advanced breast cancer who are receiving a targeted therapy called T-DXd (trastuzumab deruxtecan). Fatigue is a common side effect that can really impact quality of life.